Navigation Links
Rochester Medical Completes Acquisition of Laprolan
Date:4/7/2011

STEWARTVILLE, Minn., April 7, 2011 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ: ROCM) today announced that it has now completed the previously announced purchase of Laprolan B.V., the former Medical Supplies Division and wholly owned subsidiary of Fornix BioSciences N.V. Under the terms of the purchase agreement the purchase is deemed retroactive to January 1, 2011.  For more information regarding this transaction please refer to the Company's January 12, 2011 press release. The Company plans to further discuss this acquisition in its second quarter financial results press release and conference call which is expected to be held in early May, 2011.

Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical catheters and devices for urological and continence care applications.  The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at http://www.rocm.com.


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
2. Rochester Medical Reports First Quarter Results and Recent Developments
3. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
4. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
5. Rochester Medical Reports Fourth Quarter and Year-End Results
6. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
7. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
8. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
9. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
10. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
11. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... analysis identified the highest gene Replikin Counts in Zika history back to 1946 (1). ...
(Date:5/5/2016)... May 5, 2016  Endo International plc (NASDAQ: ... that Brian Lortie , President, U.S. Branded ... position upon the appointment of a successor. Mr. ... U.S. Pharmaceuticals business with responsibility for all strategic, ... strategy and portfolio development, commercial operations, managed markets, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... While the ... being paid to the impact our aging population has on communities and resources. Aging ... adults plan for and face age-related challenges. , Aging Life Care is a ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... long-acting injectables (LAIs), today announced a development collaboration with the Australian critical ... serious mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic ...
(Date:5/5/2016)... ... 05, 2016 , ... Textile Exchange is excited to announce the ... review. The stakeholder review is an important opportunity for interested parties to give input ... to the wool industry., The RWS is intended to be a global benchmark for ...
Breaking Medicine News(10 mins):